Cargando…

Cell-free fetal DNA testing and its correlation with prenatal indications

BACKGROUND: The prenatal test of cell-free fetal DNA (cffDNA) is also known as noninvasive prenatal testing (NIPT) with high sensitivity and specificity. This study is to evaluate the performance of NIPT and its clinical relevance with various clinical indications. METHODS: A retrospective analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing-wei, Lyu, Yong-nan, Qiao, Bin, Li, Yan, Zhang, Yan, Dhanyamraju, Pavan Kumar, Bamme, Yevgeniya, Yu, Michael D., Yang, Dongqin, Tong, Yong-qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385810/
https://www.ncbi.nlm.nih.gov/pubmed/34429082
http://dx.doi.org/10.1186/s12884-021-04044-5
_version_ 1783742164431273984
author Wang, Jing-wei
Lyu, Yong-nan
Qiao, Bin
Li, Yan
Zhang, Yan
Dhanyamraju, Pavan Kumar
Bamme, Yevgeniya
Yu, Michael D.
Yang, Dongqin
Tong, Yong-qing
author_facet Wang, Jing-wei
Lyu, Yong-nan
Qiao, Bin
Li, Yan
Zhang, Yan
Dhanyamraju, Pavan Kumar
Bamme, Yevgeniya
Yu, Michael D.
Yang, Dongqin
Tong, Yong-qing
author_sort Wang, Jing-wei
collection PubMed
description BACKGROUND: The prenatal test of cell-free fetal DNA (cffDNA) is also known as noninvasive prenatal testing (NIPT) with high sensitivity and specificity. This study is to evaluate the performance of NIPT and its clinical relevance with various clinical indications. METHODS: A retrospective analysis was conducted on 14,316 pregnant women with prenatal indications, including advanced maternal age (≥35 years), maternal serum screening abnormalities, the thickened nuchal translucency (≥2.5 mm) and other ultrasound abnormalities, twin pregnancy/IVF-ET pregnancy, etc. The whole-genome sequencing (WGS) of maternal plasma cffDNA was employed in this study. RESULTS: A total of 189 (1.32%) positive NIPT cases were identified, and 113/189 (59.79%)cases were confirmed by invasive prenatal testing. Abnormal serological screening (53.14%) was the most common indication, followed by elderly pregnancy (23.02%). The positive prediction value for T21, T18, T13, sex chromosome abnormalities, other autosomal aneuploidy abnormalities, and CNV abnormalities were 91.84, 68.75,37.50, 66.67, 14.29, and 6.45%, respectively. The positive rate and the true positive rate of nuchal translucency (NT) thickening were the highest (4.17 and 3.33%), followed by the voluntary requirement group (3.49 and 1.90%) in the various prenatal screening indications. The cffDNA concentration was linearly correlated with gestational age (≥10 weeks) and the positive NIPT group’s Z-score values. CONCLUSIONS: whole-genome sequencing of cffDNA has extremely high sensitivity and specificity for T21, high sensitivity for T18, sex chromosome abnormalities, and T13. It also provides evidence for other abnormal chromosomal karyotypes (CNV and non-21/18/13 autosomal aneuploidy abnormalities). The cffDNA concentration is closely related to the gestational age and determines the specificity of NIPT. Our results highlight NIPT’s clinical significance, which is an effective prenatal screening tool for high-quality care of pregnancy.
format Online
Article
Text
id pubmed-8385810
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83858102021-08-25 Cell-free fetal DNA testing and its correlation with prenatal indications Wang, Jing-wei Lyu, Yong-nan Qiao, Bin Li, Yan Zhang, Yan Dhanyamraju, Pavan Kumar Bamme, Yevgeniya Yu, Michael D. Yang, Dongqin Tong, Yong-qing BMC Pregnancy Childbirth Research Article BACKGROUND: The prenatal test of cell-free fetal DNA (cffDNA) is also known as noninvasive prenatal testing (NIPT) with high sensitivity and specificity. This study is to evaluate the performance of NIPT and its clinical relevance with various clinical indications. METHODS: A retrospective analysis was conducted on 14,316 pregnant women with prenatal indications, including advanced maternal age (≥35 years), maternal serum screening abnormalities, the thickened nuchal translucency (≥2.5 mm) and other ultrasound abnormalities, twin pregnancy/IVF-ET pregnancy, etc. The whole-genome sequencing (WGS) of maternal plasma cffDNA was employed in this study. RESULTS: A total of 189 (1.32%) positive NIPT cases were identified, and 113/189 (59.79%)cases were confirmed by invasive prenatal testing. Abnormal serological screening (53.14%) was the most common indication, followed by elderly pregnancy (23.02%). The positive prediction value for T21, T18, T13, sex chromosome abnormalities, other autosomal aneuploidy abnormalities, and CNV abnormalities were 91.84, 68.75,37.50, 66.67, 14.29, and 6.45%, respectively. The positive rate and the true positive rate of nuchal translucency (NT) thickening were the highest (4.17 and 3.33%), followed by the voluntary requirement group (3.49 and 1.90%) in the various prenatal screening indications. The cffDNA concentration was linearly correlated with gestational age (≥10 weeks) and the positive NIPT group’s Z-score values. CONCLUSIONS: whole-genome sequencing of cffDNA has extremely high sensitivity and specificity for T21, high sensitivity for T18, sex chromosome abnormalities, and T13. It also provides evidence for other abnormal chromosomal karyotypes (CNV and non-21/18/13 autosomal aneuploidy abnormalities). The cffDNA concentration is closely related to the gestational age and determines the specificity of NIPT. Our results highlight NIPT’s clinical significance, which is an effective prenatal screening tool for high-quality care of pregnancy. BioMed Central 2021-08-24 /pmc/articles/PMC8385810/ /pubmed/34429082 http://dx.doi.org/10.1186/s12884-021-04044-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Wang, Jing-wei
Lyu, Yong-nan
Qiao, Bin
Li, Yan
Zhang, Yan
Dhanyamraju, Pavan Kumar
Bamme, Yevgeniya
Yu, Michael D.
Yang, Dongqin
Tong, Yong-qing
Cell-free fetal DNA testing and its correlation with prenatal indications
title Cell-free fetal DNA testing and its correlation with prenatal indications
title_full Cell-free fetal DNA testing and its correlation with prenatal indications
title_fullStr Cell-free fetal DNA testing and its correlation with prenatal indications
title_full_unstemmed Cell-free fetal DNA testing and its correlation with prenatal indications
title_short Cell-free fetal DNA testing and its correlation with prenatal indications
title_sort cell-free fetal dna testing and its correlation with prenatal indications
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385810/
https://www.ncbi.nlm.nih.gov/pubmed/34429082
http://dx.doi.org/10.1186/s12884-021-04044-5
work_keys_str_mv AT wangjingwei cellfreefetaldnatestinganditscorrelationwithprenatalindications
AT lyuyongnan cellfreefetaldnatestinganditscorrelationwithprenatalindications
AT qiaobin cellfreefetaldnatestinganditscorrelationwithprenatalindications
AT liyan cellfreefetaldnatestinganditscorrelationwithprenatalindications
AT zhangyan cellfreefetaldnatestinganditscorrelationwithprenatalindications
AT dhanyamrajupavankumar cellfreefetaldnatestinganditscorrelationwithprenatalindications
AT bammeyevgeniya cellfreefetaldnatestinganditscorrelationwithprenatalindications
AT yumichaeld cellfreefetaldnatestinganditscorrelationwithprenatalindications
AT yangdongqin cellfreefetaldnatestinganditscorrelationwithprenatalindications
AT tongyongqing cellfreefetaldnatestinganditscorrelationwithprenatalindications